BIOMAT Database Logo BIOMAT Database Logo

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors. 2020

Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology and Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Peptides derived from the C-terminal heptad repeat (CHR) region of HIV-1 gp41 is potent viral membrane fusion inhibitors, such as the first clinically approved peptide drug T20 and a group of newly-designed peptides. The resistance profiles of various HIV-1 fusion inhibitors were previously characterized, and the secondary mutation N126K in the gp41 CHR was routinely identified during the in vitro and in vivo selections. In this study, the functional and structural relevance of the N126K mutation has been characterized from multiple angles. First, we show that a single N126K mutation across several HIV-1 isolates conferred mild to moderate cross-resistances. Second, the N126K mutation exerted different effects on Env-mediated HIV-1 entry and cell-cell fusion. Third, the N126K mutation did not interfere with the expression and processing of viral Env glycoproteins, but it disrupted the Asn126-based glycosylation site in gp41. Fourth, the N126K mutation was verified to enhance the thermal stability of 6-HB conformation. Fifth, we determined the crystal structure of a 6-HB bearing the N126K mutation, which revealed the interhelical and intrahelical interactions underlying the increased thermostability. Therefore, our data provide new information to understand the mechanism of HIV-1 gp41-mediated cell fusion and its resistance mode to viral fusion inhibitors.

UI MeSH Term Description Entries
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Structural and functional characterization of HIV-1 cell fusion inhibitor T20.
January 2019, AIDS (London, England),
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
October 2018, Journal of virology,
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Inhibition of HIV-1 by fusion inhibitors.
January 2010, Current pharmaceutical design,
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.
January 2017, Assay and drug development technologies,
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Functional and structural characterization of 2-amino-4-phenylthiazole inhibitors of the HIV-1 nucleocapsid protein with antiviral activity.
September 2014, ACS chemical biology,
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
HIV-1 Entry and Membrane Fusion Inhibitors.
April 2021, Viruses,
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
December 2006, Journal of molecular biology,
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Inhibiting HIV-1 entry with fusion inhibitors.
September 2003, Current medicinal chemistry,
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Current peptide HIV type-1 fusion inhibitors.
September 2009, Antiviral chemistry & chemotherapy,
Danwei Yu, and Yang Su, and Xiaohui Ding, and Yuanmei Zhu, and Bo Qin, and Huihui Chong, and Sheng Cui, and Yuxian He
Inhibition of HIV-1 group M and O isolates by fusion inhibitors.
November 2005, AIDS (London, England),
Copied contents to your clipboard!